A Phase 4, 6-week, Randomized Double Blind, Multicenter, Active-controlled Trial To Evaluate The Effects Of Celecoxib (Celebrex) Or Naproxen On Blood Pressure In Pediatric Subjects With Juvenile Idiopathic Arthritis

Trial Profile

A Phase 4, 6-week, Randomized Double Blind, Multicenter, Active-controlled Trial To Evaluate The Effects Of Celecoxib (Celebrex) Or Naproxen On Blood Pressure In Pediatric Subjects With Juvenile Idiopathic Arthritis

Completed
Phase of Trial: Phase IV

Latest Information Update: 18 Nov 2015

At a glance

  • Drugs Celecoxib (Primary) ; Naproxen
  • Indications Juvenile rheumatoid arthritis
  • Focus Pharmacodynamics
  • Sponsors Pfizer
  • Most Recent Events

    • 25 Apr 2013 Top-line results published in Pfizer Media Release.
    • 25 Apr 2013 The study was conducted as part of a post-marketing commitment to the US FDA for Celebrex, according to a Pfizer media release.
    • 25 Apr 2013 Primary endpoint 'Systolic-blood-pressure' has been met, according to a Pfizer media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top